The prevalence of trimetazidine use in athletes in Poland: excretion study after oral drug administration
- 24 November 2014
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 6 (11-12) , 1191-1196
Abstract
Stimulants, together with anabolic androgenic steroids, are regarded as one of the most popular doping substances in sport. Owing to a great variety of these substances and new designer drugs being introduced to the market, each year the World Anti‐Doping Agency (WADA) updates the list of substances and methods prohibited in sport. On 1 January 2014, a new doping agent ‐ trimetazidine (TMZ) ‐ was added to the WADA Prohibited List. TMZ, a substance prohibited in competition, is classified in the S6b Specified Stimulant Group. TMZ is used as a well‐known cardiologic drug with confirmed biochemical and clinical activity. According to knowledge of the pharmacology and mechanism of TMZ action, TMZ can be used by athletes to improve physical efficiency, especially in the case of endurance sports. This study presents the phenomena of TMZ use by Polish athletes involved in anti‐doping control in the WADA‐accredited laboratory in Warsaw (Poland) between 2008 and 2013. Samples were taken from the athletes of such disciplines as cycling, athletics, and triathlon. Moreover, the elimination study of TMZ has been conducted to establish the change of TMZ concentration in urine sample after oral administration of a single or double (during the long‐term therapy) dose. TMZ was monitored in urine samples by gas chromatography‐mass spectrometry‐nitrogen phosphorus detection (GC‐MS‐NPD). Copyright © 2014 John Wiley & Sons, Ltd.Keywords
Funding Information
- the Ministry of Sport and Tourism of the Republic of Poland (2014.0002/0305/UDOT/DWM)
This publication has 24 references indexed in Scilit:
- Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 casesFundamental & Clinical Pharmacology, 2011
- Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in FranceMovement Disorders, 2011
- Improvement of mechanical heart function by trimetazidine in db/db miceActa Pharmacologica Sinica, 2010
- Development and validation of a simple and sensitive liquid chromatography–tandem mass spectrometry method for quantifying trimetazidine in human plasmaClinical and Experimental Pharmacology and Physiology, 2010
- Trimetazidine Protective Effect Against Ischemia-Induced Susceptibility to Ventricular Fibrillation in PigsCardiovascular Drugs and Therapy, 2007
- Sensitive and rapid LC–ESI-MS method for the determination of trimetazidine in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2007
- LC/ESI-MS method for the determination of trimetazidine in human plasma: Application to a bioequivalence study on Chinese volunteersJournal of Pharmaceutical and Biomedical Analysis, 2007
- Trimetazidine: a metabolic agent for the treatment of stable anginaEuropean Heart Journal Supplements, 2001
- Effects of trimetazidine on action potentials and membrane currents of guinea-pig ventricular myocytesJournal of Molecular and Cellular Cardiology, 1986
- Antiarrhythmic Effects of Coronary Vasodilators on Canine Ventricular Arrhythmia ModelsThe Japanese Journal of Pharmacology, 1985